The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging

G. A. Ricaurte; L. E. DeLanney; K. T. Finnegan; I. Irwin; J. W. Langston

doi:10.1016/0006-8993(88)91371-6

The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging

G. A. Ricaurte, L. E. DeLanney, K. T. Finnegan, I. Irwin, J. W. Langston

School of Medicine

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The dopamine-depleting effects of intracerebroventricularly administered 6-hydroxydopamine (6-OHDA) were studied in young mature (6-8 weeks), older (8-12 months) and aged (18-24 months) mice. No differences were noted between age groups. To rule out the possibility that higher levels of monoamine oxidase (which degrades 6-OHDA) in older animals might be masking an increased sensitivity of older neurons to 6-OHDA, experiments were repeated after treatment with pargyline (50 mg/kg). Again, no differences between age groups were noted. We conclude that aging does not increase the sensitivity of dopaminergic neurons to 6-OHDA.

Original language	English (US)
Pages (from-to)	395-398
Number of pages	4
Journal	Brain research
Volume	438
Issue number	1-2
DOIs	https://doi.org/10.1016/0006-8993(88)91371-6
State	Published - Jan 12 1988

Keywords

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
6-Hydroxydopamine
Dopamine
Neurotoxicity
Parkinson's disease

ASJC Scopus subject areas

General Neuroscience
Molecular Biology
Clinical Neurology
Developmental Biology

Access to Document

10.1016/0006-8993(88)91371-6

Cite this

@article{a0c95ee2518b489695f250f0090f7308,

title = "The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging",

abstract = "The dopamine-depleting effects of intracerebroventricularly administered 6-hydroxydopamine (6-OHDA) were studied in young mature (6-8 weeks), older (8-12 months) and aged (18-24 months) mice. No differences were noted between age groups. To rule out the possibility that higher levels of monoamine oxidase (which degrades 6-OHDA) in older animals might be masking an increased sensitivity of older neurons to 6-OHDA, experiments were repeated after treatment with pargyline (50 mg/kg). Again, no differences between age groups were noted. We conclude that aging does not increase the sensitivity of dopaminergic neurons to 6-OHDA.",

keywords = "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-Hydroxydopamine, Dopamine, Neurotoxicity, Parkinson's disease",

author = "Ricaurte, {G. A.} and DeLanney, {L. E.} and Finnegan, {K. T.} and I. Irwin and Langston, {J. W.}",

note = "Funding Information: We gratefully acknowledge the technical assistance of Lorrene Davis-Ritchie, and the administrative assistance of ZoAnn McBride and David Rosn-er. This work was supported by the United Parkinson Foundation, Retirement Research Foundation, Institute for Medical Research, Santa Clara Valley Medical Center, and NIEHS G rant R01ES03697-03.",

year = "1988",

month = jan,

day = "12",

doi = "10.1016/0006-8993(88)91371-6",

language = "English (US)",

volume = "438",

pages = "395--398",

journal = "Brain research",

issn = "0006-8993",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging

AU - Ricaurte, G. A.

AU - DeLanney, L. E.

AU - Finnegan, K. T.

AU - Irwin, I.

AU - Langston, J. W.

N1 - Funding Information: We gratefully acknowledge the technical assistance of Lorrene Davis-Ritchie, and the administrative assistance of ZoAnn McBride and David Rosn-er. This work was supported by the United Parkinson Foundation, Retirement Research Foundation, Institute for Medical Research, Santa Clara Valley Medical Center, and NIEHS G rant R01ES03697-03.

PY - 1988/1/12

Y1 - 1988/1/12

N2 - The dopamine-depleting effects of intracerebroventricularly administered 6-hydroxydopamine (6-OHDA) were studied in young mature (6-8 weeks), older (8-12 months) and aged (18-24 months) mice. No differences were noted between age groups. To rule out the possibility that higher levels of monoamine oxidase (which degrades 6-OHDA) in older animals might be masking an increased sensitivity of older neurons to 6-OHDA, experiments were repeated after treatment with pargyline (50 mg/kg). Again, no differences between age groups were noted. We conclude that aging does not increase the sensitivity of dopaminergic neurons to 6-OHDA.

AB - The dopamine-depleting effects of intracerebroventricularly administered 6-hydroxydopamine (6-OHDA) were studied in young mature (6-8 weeks), older (8-12 months) and aged (18-24 months) mice. No differences were noted between age groups. To rule out the possibility that higher levels of monoamine oxidase (which degrades 6-OHDA) in older animals might be masking an increased sensitivity of older neurons to 6-OHDA, experiments were repeated after treatment with pargyline (50 mg/kg). Again, no differences between age groups were noted. We conclude that aging does not increase the sensitivity of dopaminergic neurons to 6-OHDA.

KW - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

KW - 6-Hydroxydopamine

KW - Dopamine

KW - Neurotoxicity

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0023837060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023837060&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(88)91371-6

DO - 10.1016/0006-8993(88)91371-6

M3 - Article

C2 - 3125947

AN - SCOPUS:0023837060

SN - 0006-8993

VL - 438

SP - 395

EP - 398

JO - Brain research

JF - Brain research

IS - 1-2

ER -

The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this